{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:01Z","timestamp":1791925321660,"version":"4.3.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Serum lactic acid is considered a prognostic indicator in critically ill patients. However, studies on linezolid-induced lactic acidosis (LILA) are still limited. Individuals older than 85 years old (very elderly) have limited capacity for organ compensation, and LILA data from these patients are lacking. In this study, we evaluated the risk factors for LILA in patients older than 85 years and established a risk prediction model for geriatric practice.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this retrospective cohort study, blood gas analysis data and arterial lactate levels were monitored in patients older than 85 years during the use of teicoplanin or linezolid. After propensity score matching analyses, we compared the incidence of lactic acidosis between the teicoplanin and linezolid therapy groups and identified the risk factors of LILA.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The incidence of lactic acidosis was found to be much lower in the group receiving teicoplanin than those receiving linezolid therapy (0 vs. 35.7%; <jats:italic>p<\/jats:italic> &amp;lt; 0.0001). A duration of linezolid therapy \u2265 9 days [odds ratio (OR), 3.541; 95% confidence interval (CI), 1.161\u201310.793; <jats:italic>p<\/jats:italic> = 0.026], an arterial blood glucose level \u2265 8 mmol\/L (OR, 4.548; 95% CI, 1.507\u201313.725; <jats:italic>p<\/jats:italic> = 0.007), and a high sequential organ failure assessment score (OR, 1.429; 95% CI, 1.213\u20131.685; <jats:italic>p<\/jats:italic> &amp;lt; 0.0001) were risk factors for LILA. The constructed risk model could be used to predict LILA (area under the curve, 0.849; specificity, 65.1%; sensitivity, 91.4%, with a negative predictive value of 93.2% and a positive predictive value of 59.3%).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> LILA can occur in patients older than 85 years after a relatively shorter duration of linezolid therapy. Therefore, close monitoring of blood gas and arterial lactate levels during linezolid therapy in the very elderly population is necessary.<\/jats:p>","DOI":"10.3389\/fmed.2021.604680","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:17:39Z","timestamp":1614237459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Incidence and Associated Risk Factors for Lactic Acidosis Induced by Linezolid Therapy in a Case\u2013Control Study in Patients Older Than 85 Years"],"prefix":"10.3389","volume":"8","author":[{"given":"Tingting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jionghe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guogang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1515\/cclm-2016-0438","article-title":"Lactic acidosis: an update","volume":"55","author":"Seheult","year":"2017","journal-title":"Clin Chem Lab Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13054-016-1403-5","article-title":"The value of blood lactate kinetics in critically ill patients: a systematic review","volume":"20","author":"Vincent","year":"2016","journal-title":"Crit Care."},{"key":"B3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1164\/rccm.200912-1918OC","article-title":"LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial","volume":"182","author":"Jansen","year":"2010","journal-title":"Am J Respir CritCare Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/cc8888","article-title":"Relativehyperlactatemia and hospital mortality in critically ill patients: aretrospective multi-centre study","volume":"14","author":"Nichol","year":"2010","journal-title":"Crit Care."},{"key":"B5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1021\/jm800038g","article-title":"Linezolid (ZYVOX), the first member ofa completely new class of antibacterial agents for treatment of serious gram-positive infections","volume":"51","author":"Brickner","year":"2008","journal-title":"J Med Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jac\/dkw450","article-title":"Linezolid: a promising option in the treatment of Gram-positives","volume":"72","author":"Ahedi","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1111\/aos.13237","article-title":"Clinical recovery in linezolid-induced optic nerve toxicity","volume":"95","author":"Kreps","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1592\/phco.27.8.1189","article-title":"Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome","volume":"27","author":"Narita","year":"2007","journal-title":"Pharmacotherapy."},{"key":"B12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/jac\/dkv386","article-title":"Toxicity to sensory neurons and Schwann cells in experimental linezolid-induced peripheral neuropathy","volume":"71","author":"Bobylev","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","article-title":"Peripheral neuropathy associated with prolonged use of linezolid","volume":"4","author":"Bressler","year":"2004","journal-title":"Lancet Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s15010-005-4057-9","article-title":"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases","volume":"33","author":"Ferry","year":"2005","journal-title":"Infection."},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM200301023480123","article-title":"Linezolid-induced lactic acidosis","volume":"348","author":"Apodaca","year":"2003","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/j.ejim.2008.12.002","article-title":"Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis","volume":"20","author":"Boutoille","year":"2009","journal-title":"Eur J Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.diagmicrobio.2008.08.009","article-title":"Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey","volume":"62","author":"Beekmann","year":"2008","journal-title":"Diagn Microbiol Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1128\/AAC.01190-06","article-title":"Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia","volume":"51","author":"Garrabou","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijid.2014.12.009","article-title":"Incidence and risk factors of linezolid-induced lactic acidosis","volume":"31","author":"Im","year":"2015","journal-title":"Int J Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00228-017-2377-1","article-title":"Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidenceand associated risk factors","volume":"74","author":"Mori","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e12114","DOI":"10.1097\/MD.0000000000012114","article-title":"The risk factors of linezolid-induced lactic acidosis: a case report and review","volume":"97","author":"Mao","year":"2018","journal-title":"Medicine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/501356","article-title":"Linezolid-induced inhibition of mitochondrial protein synthesis","volume":"42","author":"De Vriese","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/j.ajkd.2014.04.032","article-title":"Linezolid-induced lactic acidosis corrected with sustained low-efficiencydialysis: a case report","volume":"64","author":"Sawyer","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nrneph.2010.20","article-title":"A case of lactic acidosis induced by linezolid","volume":"6","author":"Velez","year":"2010","journal-title":"Nat Rev Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijantimicag.2011.01.025","article-title":"Early life-threatening lactic acidosis following a single infusion of linezolid","volume":"38","author":"Contou","year":"2011","journal-title":"Int J Antimicrob Agents."},{"key":"B26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1086\/499533","article-title":"Hyperlactacidemia potentially due to linezolid overexposure in a livertransplant recipient","volume":"42","author":"Pea","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/INF.0b013e3182186035","article-title":"Linezolid and lactic acidosis: a role for lactate monitoring with long-termlinezolid use in children","volume":"30","author":"Su","year":"2011","journal-title":"Pediatr Infect Dis J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1097\/CCM.0000000000001478","article-title":"Changes in whole-body oxygen consumption and skeletal musclemitochondria during linezolid-induced lactic acidosis","volume":"44","author":"Protti","year":"2016","journal-title":"Crit Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijantimicag.2014.06.017","article-title":"Early lactic cidosis associated with linezolid therapy in paediatricpatients","volume":"44","author":"Ozkaya-Parlakay","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"B30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1128\/AAC.02856-14","article-title":"Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism","volume":"58","author":"Del Pozo","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1086\/430441","article-title":"Does linezolid cause lactic acidosis by inhibiting mitochondrial proteinsynthesis?","volume":"40","author":"Palenzuela","year":"2005","journal-title":"Clin Infect Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14740338.2017.1335305","article-title":"Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes","volume":"16","author":"Santini","year":"2017","journal-title":"Expert Opin Drug Saf."},{"key":"B34","article-title":"The risk factors for linezolid-induced lactic acidosis in patients older than 85 years","author":"Liu","year":"2020","journal-title":"Res Square [Preprint]"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.604680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:17:43Z","timestamp":1614237463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.604680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":34,"alternative-id":["10.3389\/fmed.2021.604680"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.604680","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"604680"}}